image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - JP
$ 12.92
-0.996 %
$ 41 B
Market Cap
22.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one TAK stock under the worst case scenario is HIDDEN Compared to the current market price of 12.9 USD, Takeda Pharmaceutical Company Limited is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one TAK stock under the base case scenario is HIDDEN Compared to the current market price of 12.9 USD, Takeda Pharmaceutical Company Limited is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one TAK stock under the best case scenario is HIDDEN Compared to the current market price of 12.9 USD, Takeda Pharmaceutical Company Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
4.26 REVENUE
5.87%
214 B OPERATING INCOME
-56.36%
144 B NET INCOME
-54.56%
716 B OPERATING CASH FLOW
-26.69%
-464 B INVESTING CASH FLOW
23.59%
-354 B FINANCING CASH FLOW
50.02%
1.18 REVENUE
-2.65%
184 B OPERATING INCOME
-16.14%
92 B NET INCOME
-3.36%
259 B OPERATING CASH FLOW
62.51%
-80 B INVESTING CASH FLOW
50.38%
-83.2 B FINANCING CASH FLOW
-25.08%
Balance Sheet Takeda Pharmaceutical Company Limited
image
Current Assets 2.56
Cash & Short-Term Investments 458 B
Receivables 698 B
Other Current Assets 1.4
Non-Current Assets 12.6
Long-Term Investments 431 B
PP&E 1.99
Other Non-Current Assets 10.1
Current Liabilities 2.31
Accounts Payable 320 B
Short-Term Debt 367 B
Other Current Liabilities 1.63
Non-Current Liabilities 5.52
Long-Term Debt 5.03
Other Non-Current Liabilities 492 B
EFFICIENCY
Earnings Waterfall Takeda Pharmaceutical Company Limited
image
Revenue 4.26
Cost Of Revenue 1.43
Gross Profit 2.83
Operating Expenses 2.62
Operating Income 214 B
Other Expenses 70 B
Net Income 144 B
RATIOS
66.43% GROSS MARGIN
66.43%
5.02% OPERATING MARGIN
5.02%
3.38% NET MARGIN
3.38%
1.98% ROE
1.98%
0.95% ROA
0.95%
4.83% ROIC
4.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Takeda Pharmaceutical Company Limited
image
Net Income 144 B
Depreciation & Amortization 728 B
Capital Expenditures -481 B
Stock-Based Compensation 70.9 B
Change in Working Capital -256 B
Others -24.7 B
Free Cash Flow 236 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Takeda Pharmaceutical Company Limited
image
TAK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.14% DIVIDEND YIELD
0.27 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Takeda Pharmaceutical Company Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immu. businesswire.com - 3 weeks ago
Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors Takeda Pharmaceutical offers a high dividend yield, but its sustainability is questionable due to exchange rate risks and a payout ratio often exceeding 100%. Despite growth in segments like Livtencity and Qdenga, high debt and weak currency make Takeda a risky dividend investment. The devaluation of the yen against the dollar significantly impacts revenue growth and dividend stability for U.S. investors. seekingalpha.com - 1 month ago
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc.  KROS to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. benzinga.com - 1 month ago
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelo. businesswire.com - 1 month ago
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating. businesswire.com - 1 month ago
Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch Masa Takeda, portfolio manager at Hennessy Japan Fund, joins CNBC's 'Power Lunch' to discuss why he's bullish on Japan, what president-elect Trump's proposed tariffs could mean for Japanese companies, and more. youtube.com - 2 months ago
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Ramona Sequeira - President, Global Portfolio Julie Kim - President, U.S. Business Unit Giles Platford - President, PDT Business Unit Teresa Bitetti - President, Global Oncology Business Unit Conference Call Participants Steve Barker - Jefferies Mike Nedelcovych - TD Cowen Tony Ren - Macquarie Miki Sogi - Bernstein Christopher O'Reilly Thank you for taking time out of your very busy schedule to join the FY ‘24 Q2 earnings announcement by Takeda. I'm the master of ceremony, Head of IR. seekingalpha.com - 2 months ago
Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs. reuters.com - 2 months ago
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE® in the U.S.) and revised foreign exchange assumptions. T. businesswire.com - 2 months ago
Takeda Pharmaceuticals: An Interesting Option For Income Investors Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins. seekingalpha.com - 3 months ago
TAK or CTLT: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? zacks.com - 3 months ago
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 months ago
8. Profile Summary

Takeda Pharmaceutical Company Limited TAK

image
COUNTRY JP
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 41 B
Dividend Yield 0.14%
Description Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Contact 1-1, Nihonbashi-Honcho 2-chome, Tokyo, 103-8668 https://www.takeda.com
IPO Date Jan. 5, 2010
Employees 49281
Officers Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Finance Mr. Haruhiko Hirate Member of Management Board Dr. Seigo Izumo Chair of Management Board Mr. Salvatore Alesci M.D., Ph.D. Member of Management Board and Head of R&D Global Science & Biomedical Policy Mr. Christophe Weber President, Chief Executive Officer & Representative Director Mr. Iwaaki Taniguchi Senior Vice President of Corporate Finance & Controlling Department Mr. Yoshihiro Nakagawa Global General Counsel Mr. Milano Furuta Chief Financial Officer & Director Norimasa Takeda Chief Accounting Officer & Corporate Controller Mr. Gabriele Ricci Chief Data & Technology Officer